SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following the European Commission's conditional authorization of ANKTIVA, significantly expanding its market to 33 countries for hard-to-treat bladder cancer. The community is buzzing with intensifying expectations of a massive short squeeze and further global approvals, anticipating a substantial re-evaluation of the stock as a globally validated oncology company.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. ($FJET) is trending amidst high short-squeeze speculation, fueled by its extremely low float and substantial insider ownership, with the community actively debating its potential for massive gains. This excitement is further amplified by anticipation that the upcoming Space X IPO will drive the entire space sector, though some caution remains regarding the viability of air-launched small satellite ventures.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending after its earnings report delivered a revenue beat but lowered profit guidance, fueling a sell-off amid broader software sector concerns. The community is sharply divided between those predicting further declines due to acquisition costs and others viewing the dip as a significant buying opportunity, citing strong cybersecurity demand amplified by AI threats.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Activist investor Nelson Peltz's declaration that Wendy's is undervalued and his firm's exploration of significant strategic transactions, including a potential buyout, are fueling market excitement and community discussion about a potential short squeeze and the fast-food chain's future direction.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending following news of its multi-year U.S. brewing and commercial partnership with the Carlsberg Group, particularly for CBD beverages. Community discussion centers on whether this strategic collaboration signifies a major beverage market expansion and future cannabis entry for big alcohol, or if it's a non-committal deal diverting from core cannabis sector challenges.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG CRYPTO) is trending as its community celebrates nearly a year of consistently distributing passive Solana rewards to holders multiple times daily. Ongoing development, including new features, enhanced liquidity pools, and participation in the Cyberpunk Hackathon, fuels a strong bullish sentiment among its resilient 'diamond-handed' supporters.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a significant increase in institutional ownership by Cormorant Asset Management, seen by the community as a strong validation of its 'best-in-class' nanobody platform. Investors are keenly anticipating the upcoming investor day and clinical data updates, fueling speculation about a potential re-rating and short squeeze due to its perceived undervaluation and high short interest.

PENN Entertainment, Inc. engages in the provision of integrated entertainment, sports content, and casino gaming services. It operates through the following business segments: Northeast, South, West, Midwest, Interactive, and Other. The Northeast segment includes Ameristar East Chicago, Hollywood Casino, Hollywood Gaming, Marquee, and Plainridge Park Casino operations. The South segment manages 1st Jackpot Casino, Ameristar Vicksburg, Boomtown, Hollywood Casino Gulf Coast, Hollywood Casino Tunica, L’Auberge, and Margaritaville Resort Casino. The West segment is involved in Ameristar Black Hawk, Cactus Petes and Horseshu, M Resort Spa Casino, and Zia Park Casino operations. The Midwest segment focuses on Ameristar Council Bluffs, Argosy Casino, Hollywood Casino, Prairie State Gaming, and River City Casino operations. The Interactive segment refers to an online gaming portfolio which includes ESPN BET, Hollywood Casino, theScore Bet, and PENN Game Studios. The Other segment consists of stand-alone racing operations, namely Sanford-Orlando Kennel Club, Sam Houston, and Valley Race Park. The company was founded by Peter M. Carlino in 1982 and is headquartered in Wyomissing, PA.

PENN Entertainment Inc

PENN Entertainment Inc.

PENN Entertainment is trending due to widespread shareholder discontent following the costly termination of its ESPN Bet partnership and rebranding to theScore Bet, fueling calls for CEO Jay Snowden's removal. The community is actively discussing the stock's multi-year lows and advocating for a spin-off of the struggling digital betting segment to prioritize its stable regional casino operations.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop (WING) is trending after reporting a mixed Q4, with an EPS beat but a revenue miss and a conservative domestic same-store sales outlook. Despite the mixed results, the stock has shown significant relative strength and upward price action, fueling community discussions about a potential short squeeze and prompting analyst upgrades that emphasize its international growth and operational efficiency.

WorldFinancial

WorldFinancial (WLFI) is trending amidst an upcoming Mar-a-Lago forum, where potential institutional adoption and new platform launches are anticipated, while simultaneously facing intense scrutiny from a Congressional probe into its foreign investment ties. This has ignited a fierce debate within the community, split between bullish conviction in its disruptive potential and strong bearish sentiment labeling it a pump-and-dump amid regulatory concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Moderate Buy" by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One...

Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit

Executives from Lexeo Therapeutics (NASDAQ:LXEO) outlined regulatory plans, clinical data, and manufacturing updates for its lead gene therapy programs during a presentation at Guggenheim's 2026...

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2% - Time to Sell?

Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 3.2% - Should You Sell...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Moderate Buy" from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst...

Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Rises By 52.5%

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 10,830,747 shares, a...

Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Down - Here's What Happened

Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Down - What's Next...

Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9% - Still a Buy?

Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9% - Here's Why...

Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 5.5% - What's Next?

Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 5.5% - Here's What Happened...

Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 3.5% - Here's What Happened

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.5% - Time to Sell...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has earned an average rating of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

Current Price	$6.43
Prev Close	$6.28
Open	$6.26
Dividend Yield	0.00%
50-Day Moving Average	$8.56
Beta	1.96
Avg. Volume	1.26M
PE Ratio	-2.32

52-Week High	$10.99
52-Week Low	$1.45
Market Capitalization	$458.53M
EPS (Annual)	-$3.09
Price to Book	2.86
Revenue Per Employee	$0.00

LXEO
Lexeo Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXEO News

LXEOLexeo Therapeutics Inc.